Abstract Library

#4657 Should we use the growth modulation index (GMI) in response assessment in G2 neuroendocrine tumours (NETs)?

Introduction: Grade 2 (G2) neuroendocrine tumours (NETs) exhibit diverse behaviours ranging from indolent to aggressive malignancies. Growth Modulation Index (GMI) is the ratio between time to progression (TTP) with a line of therapy (TTPn) and that of the previous line of therapy (TTPn-1). A GMI value equal to or greater than 1,33 has been suggested as an indicator of clinical effectiveness beyond traditional metrics.

Conference:

Presenting Author: Bertuzzi A

Authors: Bertuzzi A, Ferrillo G, Laffi A, Evangelista L, Jandric J,

Keywords: growth modulation index (GMI), G2 gastroenteropancreatic neuroendocrine tumour (GEP-NET), tumour response assessment,

#4549 Alpha-Fetoprotein as a valuable biomarker in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a rare group of tumours that pose a significant diagnostic, therapeutic, and prognostic challenge. This complexity arises from the diversity and heterogeneity of these neoplasms, as well as from the limitations of commonly used biomarkers in clinical practice. Alpha-fetoprotein (AFP) is a fetal protein widely used primarily for congenital defects in prenatal diagnostics and in certain malignancies in adults.

Conference:

Presenting Author:

Authors: Musiałkiewicz J, Gut P, Komarnicki P, Maciejewski A, Ruchała M,

Keywords: alpha-fetoprotein, biomarker, neuroendocrine tumour,

#4329 Multivariate survival analyses of 544 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC) given first-line chemotherapy (NORDIC NEC 2)

Introduction: Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and consist of neuroendocrine tumours G3 (NET G3) and neuroendocrine carcinomas (NEC). They differ in clinical and molecular characteristics, response to treatment and prognosis. Limited prospective data are available on prognostic factors for survival in patients given first-line chemotherapy outside of clinical trials.

Conference:

Presenting Author:

Authors: Sorbye H, Hjortland G, Vestermark L, Ladekarl M, Svensson J,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, digestive, high-grade, neuroendocrine tumour grade 3,

#4208 The somatostatin system – A silent messenger in pheochromocytomas and paragangliomas?

Introduction: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) arising from neural crest-derived chromaffin cells. Due to the abundance of somatostatin receptors (SSTs) on the surface of most NENs, somatostatin analogues (SSAs) have become a cornerstone in their diagnosis and treatment. However, while PPGLs exhibit this feature, their functional responsiveness to SSAs remains limited, with the underlying cause of this resistance being still elusive.

Conference:

Presenting Author:

Authors: García Vioque V, Moreno-Montilla M, Blázquez-Encinas R, Barlier A, Arroba E,

Keywords: pheochromocytomas, paragangliomas, neuroendocrine tumor, somatostatin analogues, treatment resistance,

#3778 Biological behaviour and response to treatment of neuroendocrine ovarian metastases

Introduction: Neuroendocrine ovarian metastases (NOM) predominantly derive from midgut neuroendocrine tumors (NETs) and develop in about 25% of female patients. Little is known of the treatment response of NOM.

Conference:

Presenting Author:

Authors: Mulders M, de Lussanet de La Sablonière Q, van Velthuysen M, Hofland J, de Herder W,

Keywords: neuroendocrine, ovary, PRRT, SSA, oophorectomy, tumor, growth, rate, PFS, OS,